Cargando…

HER2-HER3 dimer quantification by FLIM-FRET predicts breast cancer metastatic relapse independently of HER2 IHC status

Overexpression of HER2 is an important prognostic marker, and the only predictive biomarker of response to HER2-targeted therapies in invasive breast cancer. HER2-HER3 dimer has been shown to drive proliferation and tumor progression, and targeting of this dimer with pertuzumab alongside chemotherap...

Descripción completa

Detalles Bibliográficos
Autores principales:	Weitsman, Gregory, Barber, Paul R., Nguyen, Lan K., Lawler, Katherine, Patel, Gargi, Woodman, Natalie, Kelleher, Muireann T., Pinder, Sarah E., Rowley, Mark, Ellis, Paul A., Purushotham, Anand D., Coolen, Anthonius C., Kholodenko, Boris N., Vojnovic, Borivoj, Gillett, Cheryl, Ng, Tony
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5239455/ https://www.ncbi.nlm.nih.gov/pubmed/27618787 http://dx.doi.org/10.18632/oncotarget.9963

Ejemplares similares

HER2-HER3 Heterodimer Quantification by FRET-FLIM and Patient Subclass Analysis of the COIN Colorectal Trial
por: Barber, Paul R, et al.
Publicado: (2019)

Assessment of EGFR/HER2 dimerization by FRET-FLIM utilizing Alexa-conjugated secondary antibodies in relation to targeted therapies in cancers
por: Waterhouse, Benjamin R., et al.
Publicado: (2011)

Robust Bayesian Fluorescence Lifetime Estimation, Decay Model Selection and Instrument Response Determination for Low-Intensity FLIM Imaging
por: Rowley, Mark I., et al.
Publicado: (2016)

Correction: Robust Bayesian Fluorescence Lifetime Estimation, Decay Model Selection and Instrument Response Determination for Low-Intensity FLIM Imaging
por: Rowley, Mark I., et al.
Publicado: (2016)

Effect of Phosphorylation on EGFR Dimer Stability Probed by Single-Molecule Dynamics and FRET/FLIM
por: Coban, Oana, et al.
Publicado: (2015)

Feedback activation of HER3 attenuates response to EGFR inhibitors in colon cancer cells
por: Bosch-Vilaró, Albert, et al.
Publicado: (2016)

Inhibitor-induced HER2-HER3 heterodimerisation promotes proliferation through a novel dimer interface
por: Claus, Jeroen, et al.
Publicado: (2018)

The potential of optical proteomic technologies to individualize prognosis and guide rational treatment for cancer patients
por: Kelleher, Muireann T., et al.
Publicado: (2009)

Impact of the OncotypeDX score and HER2 RNA PCR levels on HER2-low IHC levels in primary and metastasized tumors
por: Feldman, Didi, et al.
Publicado: (2023)

Is There any Concordance between of IHC with FISH in HER2-Positive Breast Cancer Patients?
por: Payandeh, Mehrdad, et al.
Publicado: (2017)

Breast Cancer With a HER2 IHC2+ and FISH HER2/CEP17 Ratio ≥2.0 and an Average HER2 Gene Copy Number <4.0 per Tumor Cell: HER2 mRNA Overexpression Is a Rare Event
por: Liu, Yuanyuan, et al.
Publicado: (2020)

Comparison of immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) assessment for Her-2 status in breast cancer
por: Sui, Weiguo, et al.
Publicado: (2009)

A comparative study of gastric adenocarcinoma HER2 IHC phenotype and mass spectrometry-based quantification
por: Xu, Bin, et al.
Publicado: (2023)

HER kinase inhibition in patients with HER2- and HER3-mutant cancers
por: Hyman, David M., et al.
Publicado: (2018)

Prognostic value of HER2 status in bladder transitional cell carcinoma revealed by both IHC and BDISH techniques
por: Nedjadi, Taoufik, et al.
Publicado: (2016)

A Retrospective Hospital-Based Study of HMGCR Expression in HER2 IHC 2+ and 3+ Breast Cancer
por: Mohamed, Malisalaora, et al.
Publicado: (2021)

Concomitant Detection of HER2 Protein and Gene Alterations by Immunohistochemistry (IHC) and Silver Enhanced In Situ Hybridization (SISH) Identifies HER2 Positive Breast Cancer with and without Gene Amplification
por: Varga, Zsuzsanna, et al.
Publicado: (2014)

Predicting Effects of Clinicopathological Variables on Her2 Gene Amplification by Chromogenic in situ Hybridization (CISH) in IHC Her2 (2+) Breast Cancer Patients; A Study from Iran
por: Hashemi Bahremani, Mohammad, et al.
Publicado: (2020)

Cytogenetic analysis of HER1/EGFR, HER2, HER3 and HER4 in 278 breast cancer patients
por: Sassen, Andrea, et al.
Publicado: (2008)

HER2 Basolateral versus Circumferential IHC Expression Is Dependent on Polarity and Differentiation of Epithelial Cells in Gastric/GE Adenocarcinoma
por: Pervez, Shahid, et al.
Publicado: (2018)

The role of HER2 and HER3 in HER2-amplified cancers beyond breast cancers
por: Majumder, Avisek, et al.
Publicado: (2021)

Practical and reliable FRET/FLIM pair of fluorescent proteins
por: Shcherbo, Dmitry, et al.
Publicado: (2009)

Model-Based Analysis of HER Activation in Cells Co-Expressing EGFR, HER2 and HER3
por: Shankaran, Harish, et al.
Publicado: (2013)

The relation between survival and expression of HER1 and HER2 depends on the expression of HER3 and HER4: a study in bladder cancer patients
por: Memon, A A, et al.
Publicado: (2006)

Evaluation of HER-2/neu status in breast cancer specimens using immunohistochemistry (IHC) & fluorescence in-situ hybridization (FISH) assay
por: Goud, Kalal Iravathy, et al.
Publicado: (2012)

Investigating the Relationship between of Vascular Endothelial Growth Factor and HER-2neu in IHC Staining with Metastasis and Mortality in Patients with Osteosarcoma
por: Aznab, Mozaffar, et al.
Publicado: (2020)

Liquid Biopsy and Tissue Biopsy Comparison with Digital PCR and IHC/FISH for HER2 Amplification Detection in Breast Cancer Patients
por: Xie, Suhong, et al.
Publicado: (2022)

“Everything for Her!”
por: Andrijević Matovac, Vesna
Publicado: (2011)

In her family /
por: Metheny, Pat
Publicado: (1987)

FLIM-FRET analyzer: open source software for automation of lifetime-based FRET analysis
por: Kim, Jiho, et al.
Publicado: (2017)

HER2/HER3 heterodimers and p21 expression are capable of predicting adjuvant trastuzumab response in HER2+ breast cancer
por: Green, Andrew R., et al.
Publicado: (2014)

ADVICE TO THE EXPECTANT MOTHER ON THE CARE OF HER HEALTH AND THAT OF HER CHILD
Publicado: (1947)

HER-3 expression in HER-2-amplified breast carcinoma
por: Czopek, Jacek, et al.
Publicado: (2013)

Advice to the Expectant Mother on the Care of Her Health and That of Her Child
Publicado: (1947)

Advice to the Expectant Mother on the Care of Her Health and That of Her Child
Publicado: (1943)

Advice to the Expectant Mother on the Care of Her Health and That of Her Child
Publicado: (1941)

HER3, p95HER2, and HER2 protein expression levels define multiple subtypes of HER2-positive metastatic breast cancer
por: Lipton, Allan, et al.
Publicado: (2013)

Correlation of HER2, p95HER2 and HER3 Expression and Treatment Outcome of Lapatinib plus Capecitabine in her2-Positive Metastatic Breast Cancer
por: Han, Sae-Won, et al.
Publicado: (2012)

Dynamic FRET-FLIM based screening of signal transduction pathways
por: Harkes, Rolf, et al.
Publicado: (2021)

Comparison of tumors with HER2 overexpression versus HER2 amplification in HER2-positive breast cancer patients
por: Horimoto, Yoshiya, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ldhpcflua8vtp8klrccbd562f4